ClinicalTrials.gg
RecruitingNCT06931769TAOUpdated Oct 7, 2026

TAO-Towards Optimal (Neo)Adjuvant Systemic Therapy of Stage III Triple-negative Breast Cancer

An observational study in Breast Cancer, sponsored by The Netherlands Cancer Institute. Recruiting at 9 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by The Netherlands Cancer Institute · Observational

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.
Updated Oct 7, 2026Site recruiting status changed2 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 48 studies in Breast Neoplasms by The Netherlands Cancer Institute — 16 open to participants now, 25 under way, 7 of them phase 3. Breast Neoplasms · The Netherlands Cancer Institute.

Started
2025
with 3 others
Observational
5 of 48
3 open now
Primary completion
2029-07
later than 18 of 24 live
Registered
44th of 48
by date

Among the 48 studies in Breast Neoplasms by The Netherlands Cancer Institute, this one is one of 4 that started in 2025, is one of 5 observational ones, reaches primary completion later than 18 of the 24 other live ones, and was the 44th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

16 of the 48 studies in Breast Neoplasms by The Netherlands Cancer Institute are open now, in 2 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Breast Neoplasms by The Netherlands Cancer Institute, or all of them as a file.
02

Study summary

This prospective, national, multi-centre study will include patients with stage III triple-negative breast cancer (TNBC) who are planned to start with standard (neo)adjuvant systemic treatment. The study will gather clinico-pathological, treatment and follow-up information of participating patients through Dutch databases. Participating patients will be asked to complete cancer specific and more generic quality of life questionnaires at nine time points during and after their anticancer treatment in a mobile application.

For all patients who have consented to additional blood collection, to assess the course of dynamic ctDNA during (neo)adjuvant chemotherapy and its relation with outcome, two tubes will be collected at four different time points.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Stage III
  • Triple Negative
  • Neo adjuvant treatment
  • Quality of Life
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients diagnosed with stage III, hormone receptor (HR)-negative HER2-negative, adenocarcinoma of the breast (TNBC).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18 years or older
  • confirmed adenocarcinoma of the breast
  • Assumed clinical or pathological stage III (TNM) breast cancer
  • Breast tumor must be:

    • -negative: i.e. either score 0 or 1 at immunohistochemistry or score 2 at immunohistochemistry and negative at in situ hybridization (ISH, CISH or FISH)
    • Hormone receptor negative i.e. an estrogen receptor (ER) of \<10% and progesterone receptor (PR) of \<10%.; or in case of a histological grade III tumor an ER of \<50% and a PR of \<50%.
  • Patients are planned to receive the complete standard of care in the Netherlands; chemotherapy according to local practise
  • Participating patients have to be able to use a mobile phone, tablet, laptop and/or computer and understand the Dutch language

Exclusion criteria

Exclusion Criteria:

  • Evidence of distant . Staging examinations should have been performed according to Dutch national guidelines.
  • Patients who are only treated systemically in the setting
  • Participation in another clinical study with an treatment intervention during the course of this study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. To determine the effects of the standard (neo)adjuvant systemic treatment on health-related quality of life (HRQoL) for patients with stage III TNBC. Questionnaire 1.

    The HRQoL will be assessed through the following questionnaire: • European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ C30)

    Time frame: Up to 36 months after surgery

  2. To determine the effects of the standard (neo)adjuvant systemic treatment on health-related quality of life (HRQoL) for patients with stage III TNBC. Questionnaire 2.

    The HRQoL will be assessed through the following questionnaire: • European Organization for Research and Treatment of Breast Cancer specific Quality of Life Questionnaire (EORTC QLQ BR23)

    Time frame: Up to 36 months after surgery

  3. To determine the effects of the standard (neo)adjuvant systemic treatment on health-related quality of life (HRQoL) for patients with stage III TNBC. Questionnaire 3.

    The HRQoL will be assessed through the following questionnaire: • Functional assessment of cancer therapy - endocrine symptoms (FACT-ES)

    Time frame: Up to 36 months after surgery

Secondary outcomes

  1. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

    Toxicity will be measured on a per-patient basis and assessed as a proportion of the total study population.

    Time frame: Up to 24 months after start treatment

  2. Cognitive functioning - Questionnaire

    Cognitive functioning will be measured using the cognitive functioning questionnaire at baseline and follow-up. This will be measured before and after standard (neo)adjuvant systemic therapy.

    Time frame: Up to 36 months after surgery

  3. Cognitive functioning - ASC (Amsterdam Cognition Scan)

    Cognitive functioning will be measured using the ASC (Amsterdam Cognition Scan) at baseline and follow-up. This will be measured before and after standard (neo)adjuvant systemic therapy. The ACS will determine the cognitive test performance through seven cognitive tests with 11 outcome measures. In this study the score differences in cognitive functioning between baseline and the two follow-up time points at 24 and 36 months after surgery will be calculated for patients treated with standard systemic therapy.

    Time frame: Up to 36 months after surgery

  4. Oral health related quality of life (QoL) - EORTC-QLQ-OH15

    The EORTC-QLQ-OH15 will provide a detailed overview of oral health symptoms associated with cancer. The EORTC-QLQ-OH15 will be shortened to a 11-item questionnaire with a 4-point scoring scale defined by the terms: not at all, a little, quite a bit and very much.

    Time frame: Up to 36 months after surgery

  5. Oral health related quality of life (QoL) - Xerostomia Inventory

    The shortened Xerostomia Inventory will provide a detailed overview of oral health symptoms associated with cancer. The shortened Xerostomia Inventory includes 5 items with a 3-point scoring system defined by the terms: never, sometimes, always.

    Time frame: Up to 36 months after surgery

  6. Oral health related quality of life (QoL) - Oral Impact on Daily Performance index

    The Oral Impact on Daily Performance index will include 6 questions with a 6-point scoring system assessing the influence of oral health related problems on daily life functions.

    Time frame: Up to 36 months after surgery

  7. Oral health related quality of life (QoL) - oral self-care questionnaire

    The oral self-care questionnaire will provide further insights in the differences in oral care routines during follow-up. At baseline the self-care questionnaire will include 5 items compared to only 2 items at follow up.

    Time frame: Up to 36 months after surgery

  8. Resource use - Dutch hospital data (DHD)

    Resource use will be measured using the Dutch hospital data (DHD). The costs of the standard of care will be estimated using data on patient's treatments from the Dutch Hospital Database (DHD). These results will be implemented in a cost-effectiveness model.

    Time frame: Up to 36 months after surgery

  9. Costs - Dutch hospital data (DHD)

    Costs will be measured using the Dutch hospital data (DHD). The costs of the standard of care will be estimated using data on patient's treatments from the Dutch Hospital Database (DHD). These results will be implemented in a cost-effectiveness model.

    Time frame: Up to 36 months after surgery

  10. Resource use - iMTA Medical Consumption Questionnaire (iMCQ)

    Resource use will be measured using iMTA Medical Consumption Questionnaire (iMCQ). It is a not disease-specific questionnaire, which includes questions related to frequently occurring contacts with health care providers.

    Time frame: Up to 36 months after surgery

  11. Resource use - iMTA Productivity Cost Questionnaire (iPCQ)

    Resource use will be measured using the iMTA Productivity Cost Questionnaire (iPCQ). The iMTA Productivity Cost Questionnaire (iPCQ) measures the impact of disease on the ability to perform work.

    Time frame: Up to 36 months after surgery

  12. Overall survival (OS)

    Number of patients alive and dead

    Time frame: Up to 36 months after surgery

  13. Event-free survival

    Number of patients with recurrence of disease

    Time frame: Up to 36 months after surgery

  14. ctDNA dynamics

    The levels of ctDNA at different time points will be assessed to determine ctDNA dynamic changes during standard of care (neo)adjuvant systemic therapy and their relation to treatment outcome.

    Time frame: Up to 36 months after surgery

07

Study locations

6 of 9 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Jul 2029, 43 months after the start.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 43 months is below that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2024
First posted
Apr 17, 2025
StartActual
Nov 6, 2025
Primary completionEst.
Jul 1, 2029
CompletionEst.
Jul 1, 2030
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added. Amphia is now Recruiting
Show 2 added (2 Netherlands)
  • Deventer ziekenhuis · Deventer, Netherlands
  • CWZ · Nijmegen, Netherlands
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    2 sites added. Amphia is now Recruiting
    Show 2 added (2 Netherlands)
    • Deventer ziekenhuis · Deventer, Netherlands
    • CWZ · Nijmegen, Netherlands
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06931769
Collaborators
Dutch Cancer Society
Responsible party
Sponsor
First posted
Apr 17, 2025
Start date
Nov 6, 2025
Primary completion
Jul 1, 2029 (estimated)
Completion
Jul 1, 2030 (estimated)
Last update
Oct 7, 2026

Study contacts

Pien Debets, Study coordinator
Contact
p.debets@nki.nl
0205129111
Ingrid Mandjes, Clinical Projects Manager
Contact

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion